Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

ClinicalTrials.gov ID: NCT07837830

Public ClinicalTrials.gov record NCT07837830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension: A Prospective Open-Label Matched Control Pilot Trial.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This prospective open-label matched-control pilot study evaluates whether inhaled treprostinil improves exercise pulmonary vascular resistance and functional outcomes in adults with interstitial lung disease or connective tissue disease and exercise-induced pulmonary hypertension. Participants will receive inhaled treprostinil plus standard care or standard care alone and will be followed for 6 months, with an optional extension to 12 months.

Study identification

NCT ID: NCT07837830
Recruitment status: Recruiting
Study type: Interventional
Phase: Early Phase 1
Lead sponsor: Valley Health System; Other
Enrollment: 32 participants

Conditions and interventions

Conditions

Pulmonary Hypertension

Interventions

Treprostinil Drug
Standard of Care Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2026 (Estimated)
Primary completion: Dec 2027 (Estimated)
Completion: Jun 2028 (Estimated)
Last update posted: Sep 24, 2026

2026 – 2028

United States locations

U.S. sites: 2
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
The Valley Hospital	Paramus	New Jersey	07652	Recruiting
Valley Medical Group Pulmonary Hypertension Clinic	Paramus	New Jersey	07652	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07837830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 24, 2026 · Synced Nov 10, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07837830 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →